London, 29-30 April
Latest News
Upcoming Events
Amphista will be attending and/or presenting at the following conferences. If you would like to meet with us, please email info@amphista.com
Protein Degradation in Focus Symposium
Dundee, 19-22 May
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
Amphista and Bristol Myers Squibb to collaborate and leverage Amphista’s proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics Collaboration includes an upfront payment of $30 million, the potential for up to $1.25 billion in performance-based milestone payments and payments for a limited expansion of the collaboration, as well as royalties on […]
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
Amphista and Merck will collaborate to leverage Amphista’s proprietary Eclipsys™ TPD platform and generate novel protein degrading therapeutics in oncology and immunology Collaboration includes up to €39 million ($44 million*) in combined upfront and R&D funding payments for an initial three programs Amphista will potentially receive up to €893.5 million ($1.0 billion*) in total payments […]
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Cambridge, England, 6 December 2021 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO). Martin joins Amphista from AstraZeneca, where he was Vice President, Head Early Oncology Projects and led successful clinical development efforts. Martin has over 30 […]